Company Overview and News

2
SNDX / Syndax Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
sndx-10q_20180630.htm UNITED STATES
SNDX

2
SNDX / Syndax Pharmaceuticals, Inc. S-8

2018-08-08 sec.gov
sndx-s8.htm As filed with the Securities and Exchange Commission on August 8, 2018
SNDX

5
Syndax Pharmaceuticals, Inc.'s (SNDX) CEO Briggs Morrison on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha - 3
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2018 Results Earnings Conference Call August 7, 2018 8:00 AM ET
MS SNDX

2
SNDX / Syndax Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-08 sec.gov
sndx-8k_20180807.htm
SNDX

68
6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst - 13
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside.
EIDX MGTA INNT GLMD RARX SNDX

9
SNDX / Syndax Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-20 sec.gov - 4
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SNDX

5
SNDX / Syndax Pharmaceuticals, Inc. null

2018-06-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
SNDX

36
Vical's stock plunges 23% premarket after genital herpes treatment fails in phase 2 trial

2018-06-11 marketwatch - 1
Vical Inc. said Monday a phase 2 trial of its treatment for genital herpes failed to meet its primary endpoint of annualized lesion recurrence rate. The stock was still inactive in premarket trade. In a study of 261 healthy adults with herpes simplex virus type 2, aged 18 to 50, with a self-reported history of 4 to 9 recurrences a year, Vical said the annualized recurrence rate in the placebo group was "far less" than what was expected, meaning there was "significantly less power" to show a vaccine effect in the trial.
ARE CYORP ICFI WIRE MBUU CIO GNCA SNDX VICL

351
This One Study Could Radically Change The Cancer Immunotherapy Market

2018-06-07 seekingalpha - 3
The cause is speculated to be that antibiotics clear the gut of bacteria, which decreases the amount of circulating immune cells, which in turn lessens the effect of immunotherapy.
SGEN MRK TSRO AMGN BMYMP ADXS BLUE CELG BLUE SNDX BMY

152
Your Daily Pharma Scoop: Crispr On Hold, AstraZeneca Stumbles Again, TherapeuticsMD Receives FDA Approval

2018-05-31 seekingalpha - 2
Crispr Therapeutics (NASDAQ:CRSP) is one of the three companies that specialises in CRISPR-Cas9 genome editing technique. All three companies had spectacular IPOs but presently Crispr Therapeutics is the only one that has retained the initial euphoria and has become a $3.472B company in less than three years. Yesterday the stock slumped ~20%. The slump apparently resulted from the company’s disclosure that the FDA placed a clinical hold on its IND for gene therapy candidate CTX001 for sickle cell disease (‘SCD).
NKTR MBIO KIN VRTX TXMD GILD AZN GLPG CRSP ARWR GLPG DRNA SAGE AZN ACRS NVS FPRX SNDX

7
Nektar Therapeutics’ Big Week: Syndax Cancer Collaboration and New Opioid Submission

2018-05-31 biospace - 1
It’s been a busy week for Nektar Therapeutics. The company announced today that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NKTR-181, a new molecular entity (NME), a mu-opioid agonist for pain relief. Yesterday it inked a non-exclusive, clinical collaboration deal with Syndax Pharmaceuticals to develop Nektar’s NKTR-214, a CD122-biased agonist in combination with entinostat, Syndax’s HDAC inhibitor in metastatic melanoma.
NKTR SNDX

40
Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial

2018-05-28 seekingalpha - 1
Syndax is a strong grower brewing two stellar molecules (entinostat and SNDX-6352). Most value resides in the entinostat franchises (either as a monotherapy or in combinations with other flagship drugs.
EXEL MRK SNDX

5
SNDX / Syndax Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-27 sec.gov
sndx-8k_20180523.htm UNITED STATES
SNDX

8
Syndax: One Step Backward, Two Forward?

2018-05-23 seekingalpha
Today, we look at a small biotech called Syndax Pharmaceuticals whose stock fell 25% last week on a setback in a trial.
MRK SNDX

7
Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?

2018-05-21 seekingalpha - 1
Syndax Pharmaceuticals reports that the entire NSCLC population didn't do well with its entinostat combo, however a subpopulation with high levels of monocytes performed much better.
L SNDX

Related Articles

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

CUSIP: 87164F105